Abstract 304P
Background
The EXTREME trial demonstrated that patients with R/M-HNSCC benefit from the addition of cetuximab to first-line platinum-based CT in relation to overall survival (OS), progression-free survival (PFS) and response rate. The aims of the study are to evaluate the survival outcomes and identify predictors of survival among these patients (pts).
Methods
Data regarding R/M HNSCC consecutive pts treated with cetuximab and platinum from 2009 to 2018 were retrospectively collected. The analyses of response (R.), PFS and OS, each evaluated starting from first treatment, were performed. A Cox proportional hazard model was run and Survival curves were estimated with the Kaplan-Meier method and compared using the log-rank test.
Results
108 pts were identified with ECOG-PS 0-1. Median age was 57 years (y.) (36-74y.) Primary tumor sites were oropharynx 28(25,9%), oral cavity 19 (17,6%), larynx/hypopharynx 57 (52,7%) and others 4 (3,7%). Median OS was 16,9 months (m). (95% confidence interval [CI] 12,9-20,9), and mean PFS was 7,4 m. (95% CI 4,1-8,9). 43 pts (39,8%) completed 6 cycles of treatment. R. rate (partial R. and complete R.) was 19%, with 31 (28,7%) showing stable disease. ECOG-PS 1 (HR = 1.71,95% CI 1,1-2,97) and the location of the primary tumor in the larynx/hypopharynx (HR = 1.98, 95% CI 1,14-3,48) were significantly associated with an increased risk of disease progression.48 (44%) pts who received CT plus cetuximab continued to receive cetuximab until disease progression or unacceptable toxic effects with statistical significant differences between this sub-group and those who weren’t able to receive Cetuximab monotherapy (OS 23,6m. (95% CI 16,1-31,1) vs 10,9 m. (95% CI 8,7-13,1) p = 0,001). OS was higher in pts with grade 2-4 skin toxicity associated with cetuximab (OS 18,4m. (95% CI 13.7-23.1) vs 13,7m. (95% CI 8,7-18,8) p = 0.05).
Conclusions
In non-selected R/M HNSCC pts, we obtained a median PFS and OS of 7,4 and 16,9 months, superior to 5,6 and 10,1 months reported in Extreme trial (Vermorken et al. 2008). ECOG PS, larynx/hypopharynx location and skin toxicity related to Cetuximab could be used to define pt prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy
Presenter: Alekhya Mandepudi
Session: Poster display session
Resources:
Abstract
449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients
Presenter: PRUTHVI Paibhavi
Session: Poster display session
Resources:
Abstract
450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review
Presenter: Rainer Spiegel
Session: Poster display session
Resources:
Abstract
451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Presenter: Nobuhiro Hattori
Session: Poster display session
Resources:
Abstract
452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count
Presenter: Irza Wahid
Session: Poster display session
Resources:
Abstract
453P - Body mass index did not correlate with short term overall survival in breast cancers
Presenter: Jungsun Lee
Session: Poster display session
Resources:
Abstract
454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
Presenter: Sangana Reddy
Session: Poster display session
Resources:
Abstract
455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
Presenter: Sri Prathima
Session: Poster display session
Resources:
Abstract
456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
Presenter: Anchal Mishra
Session: Poster display session
Resources:
Abstract
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract